Cited by 724PI3K/AKT/mTOR signaling in cancerTuberous Sclerosis Complex ResearchMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

A complex interplay between Akt, TSC2 and the two mTOR complexes

Open access

Huang, Jingxiang, Manning, Brendan D.·2009·Biochemical Society Transactions

Open this paper in CoChat — free account

Abstract

Akt/PKB (protein kinase B) both regulates and is regulated by the TSC (tuberous sclerosis complex) 1–TSC2 complex. Downstream of PI3K (phosphoinositide 3-kinase), Akt phosphorylates TSC2 directly on multiple sites. Although the molecular mechanism is not well understood, these phosphorylation events relieve the inhibitory effects of the TSC1–TSC2 complex on Rheb and mTORC1 [mTOR (mammalian target of rapamycin) complex] 1, thereby activating mTORC1 in response to growth factors. Through negative-feedback mechanisms, mTORC1 activity inhibits growth factor stimulation of PI3K. This is particularly evident in cells and tumours lacking the TSC1–TSC2 complex, where Akt signalling is severely attenuated due, at least in part, to constitutive activation of mTORC1. An additional level of complexity in the relationship between Akt and the TSC1–TSC2 complex has recently been uncovered. The growth-factor-stimulated kinase activity of mTORC2 [also known as the mTOR–rictor (rapamycin-insensitive companion of mTOR) complex], which normally enhances Akt signalling by phosphorylating its hydrophobic motif (Ser473), was found to be defective in cells lacking the TSC1–TSC2 complex. This effect on mTORC2 can be separated from the inhibitory effects of the TSC1–TSC2 complex on Rheb and mTORC1. The present review discusses our current understanding of the increasingly complex functional interactions between Akt, the TSC1–TSC2 complex and mTOR, which are fundamentally important players in a large variety of human diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1042/bst0370217

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Self-citation
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Mechanism of activation of protein kinase B by insulin and IGF‐1.
Alessi, D. R., Andjelković, M., Caudwell, B., Cron, P. D., MORRICE, N. A., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,014
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Show all 35 references

Sorted by citations

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression
Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395
Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks
Alers, S., Löffler, A. S., Wesselborg, S., & Stork, B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06159-11 · Cited by 1,483
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration
Heras-Sandoval, D., Pérez-Rojas, J. M., Hernández-Damián, J., & Pedraza-Chaverri, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.019 · Cited by 1,091
The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
Sun, K., Luo, J., Guo, J., Yao, X., Jing, X., & Guo, F. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.02.027 · Cited by 685
Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways
Yecies, J. L., Zhang, H., Menon, S., Liu, S., Yecies, D. W., Lipovsky, A. I., Görgün, C. Z., Kwiatkowski, D. J., Hotamışlıgil, G. S., Lee, C., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.002 · Cited by 685
Self-citation
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646
The TSC-mTOR pathway regulates macrophage polarization
Byles, V., Covarrubias, A. J., Ben‐Sahra, I., Lamming, D. W., Sabatini, D. M., Manning, B. D., & Horng, T. (2013) · Nature Communications · doi:10.1038/ncomms3834 · Cited by 646
Self-citation
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 652
TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
Dibble, C. C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J. M., Finan, P. M., Kwiatkowski, D. J., Murphy, L. O., & Manning, B. D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.009 · Cited by 612
Self-citation
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 579
Axon degeneration in Parkinson's disease
Burke, R. E., & O’Malley, K. L. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 514
Rapamycin Protects against Neuron Death inIn VitroandIn VivoModels of Parkinson's Disease
Malagelada, C., Jin, Z. H., Jackson-Lewis, V. R., Przedborski, S., & Greene, L. A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3944-09.2010 · Cited by 465
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirović, I., Fonseca, B. D., & Sonenberg, N. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 471
Unraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 457
mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 452
mTOR signaling and drug development in cancer
Dancey, J. E. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 426
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesisPreprint
Wei, H., Wei, S., Gan, B., Xu, P., Zou, W., & Guan, J. (2011) · Genes & Development · doi:10.1101/gad.2051011 · Cited by 414
Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
Zhang, H., Huang, J., Düvel, K., Boback, B. B., Wu, S., Squillace, R. M., Wu, C., & Manning, B. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006189 · Cited by 406
Self-citation
Amino Acid Starvation Induced by Invasive Bacterial Pathogens Triggers an Innate Host Defense Program
Tattoli, I., Sorbara, M. T., Vuckovic, D., Ling, A., Soares, F., Carneiro, L. A. M., Yang, C., Emili, A., Philpott, D. J., & Girardin, S. E. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.04.012 · Cited by 376
First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Sarker, D., Ang, J., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P., Raynaud, F., Levy, G., Ware, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 285
Regulation of presynaptic neurotransmission by macroautophagy
Hernandez, D., Torres, C. A., Setlik, W., Cebrián, C., Mosharov, E., Tang, G.-M., Cheng, H.-C., Kholodilov, N., Yarygina, O., Burke, R., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.020 · Cited by 346
Untitled work
(2010) · PubMed Central
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 338
SIRT1 Promotes Proliferation and Prevents Senescence Through Targeting LKB1 in Primary Porcine Aortic Endothelial Cells
Zu, Y., Liu, L., Lee, M. Y. K., Xu, C., Liang, Y., Man, R. Y., Vanhoutte, P. M., & Wang, Y. (2010) · Circulation Research · doi:10.1161/circresaha.109.215483 · Cited by 303
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications
Ostrovidov, S., Hosseini, V., Ahadian, S., Fujie, T., Parthiban, S. P., Ramalingam, M., Bae, H., Kaji, H., & Khademhosseini, A. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0534 · Cited by 302
Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3+ regulatory T cells
Strainic, M. G., Shevach, E. M., An, F., Lin, F., & Medof, M. E. (2012) · Nature Immunology · doi:10.1038/ni.2499 · Cited by 308
Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action
Freyberg, Z., Ferrando, S. J., & Javitch, J. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08121873 · Cited by 288
The multifaceted role of mTORC1 in the control of lipid metabolism
Ricoult, S. J. H., & Manning, B. D. (2013) · EMBO Reports · doi:10.1038/embor.2013.5 · Cited by 291
Self-citation
mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1–JNK pathway
Kato, H., Nakajima, S., Saito, Y., Takahashi, S., Katoh, R., & Kitamura, M. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.98 · Cited by 273
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway
Gurusamy, N., Lekli, I., Mukherjee, S., Ray, D., Ahsan, M. K., Gherghiceanu, M., Popescu, L. M., & Das, D. K. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp384 · Cited by 267
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 258
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
O'Brien, C. L., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H. M., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 256
Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways
Wang, Y., Xu, W., Yan, Z., Zhao, W., Mi, J., Li, J., & Yan, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0731-5 · Cited by 258
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapyPreprint
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 259
Targeting autophagy-related protein kinases for potential therapeutic purpose
Xiang, H., Zhang, J., Lin, C., Zhang, L., Liu, B., & Ouyang, L. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.003 · Cited by 258
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Martelli, A. M., Evangelisti, C., Chiarini, F., & McCubrey, J. A. (2010) · Oncotarget · doi:10.18632/oncotarget.114 · Cited by 251
Amino Acid Signaling in TOR Activation
Kim, J., & Guan, K. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062209-094414 · Cited by 239
Translational animal models of autism and neurodevelopmental disorders
Crawley, J. N. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.3/jcrawley · Cited by 236
AMPK directly activates mTORC2 to promote cell survival during acute energetic stress
Kazyken, D., Magnuson, B., Bodur, Ç., Acosta-Jaquez, H. A., Zhang, D., Tong, X., Barnes, T. M., Steinl, G. K., Patterson, N., Altheim, C. H., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav3249 · Cited by 226
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
Johnston, P. B., Inwards, D. J., Colgan, J. P., LaPlant, B. R., Kabat, B., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21664 · Cited by 219
Temsirolimus Activates Autophagy and Ameliorates Cardiomyopathy Caused by Lamin A/C Gene Mutation
Choi, J. C., Muchir, A., Wu, W., Iwata, S., Homma, S., Morrow, J., & Worman, H. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003875 · Cited by 228
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
Ehninger, D., & Silva, A. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.002 · Cited by 223
The Insulin-Like Growth Factor System in Cancer
Weroha, S. J., & Haluska, P. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.014 · Cited by 213
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies.
Wong, M. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02341.x · Cited by 205
Mouse Cardiac Acyl Coenzyme A Synthetase 1 Deficiency Impairs Fatty Acid Oxidation and Induces Cardiac Hypertrophy
Ellis, J. M., Mentock, S. M., DePetrillo, M. A., Koves, T. R., Sen, S., Watkins, S. M., Muoio, D. M., Cline, G. W., Taegtmeyer, H., Shulman, G. I., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01085-10 · Cited by 194
Balanced mTORC1 Activity in Oligodendrocytes Is Required for Accurate CNS Myelination
Lebrun-Julien, F., Bachmann, L. C., Norrmén, C., Trötzmüller, M., Köfeler, H. C., Rüegg, M. A., Hall, M. N., & Suter, U. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1105-14.2014 · Cited by 199
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
MacKeigan, J. P., & Krueger, D. A. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov152 · Cited by 185
EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
Freudlsperger, C., Burnett, J. R., Friedman, J., Kannabiran, V. R., Chen, Z., & Waes, C. V. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541440 · Cited by 183
Conserved insulin signaling in the regulation of oocyte growth, development, and maturation
Das, D., & Arur, S. (2017) · Molecular Reproduction and Development · doi:10.1002/mrd.22806 · Cited by 183
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Regulation of Autophagy by Kinases
Sridharan, S., Jain, K., & Basu, A. (2011) · Cancers · doi:10.3390/cancers3022630 · Cited by 189
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes
Pal, I., & Mandal, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.72 · Cited by 183
Behavioral phenotypes of genetic mouse models of autism
Kazdoba, T. M., Leach, P. T., & Crawley, J. N. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12256 · Cited by 187
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
Aller, G. S. V., Carson, J. D., Tang, W. D., Peng, H., Zhao, L., Copeland, R. A., Tummino, P. J., & Luo, L. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.010 · Cited by 178
D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance
Larner, J., Brautigan, D. L., & Thorner, M. O. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00107 · Cited by 177
mTORC2: The other mTOR in autophagy regulation
Ballesteros‐Álvarez, J., & Andersen, J. K. (2021) · Aging Cell · doi:10.1111/acel.13431 · Cited by 187
Longevity, aging and rapamycin
Ehninger, D., Neff, F., & Xie, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1677-1 · Cited by 183
Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway
Chen, A., Xiong, L.-J., Yu, T., & Mao, M. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1628 · Cited by 181
The PI3K/Akt/PTEN/mTOR Pathway: A Fruitful Target for Inducing Cell Death in Rheumatoid Arthritis?
Malemud, C. J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.55 · Cited by 177
Eat to reproduce: a key role for the insulin signaling pathway in adult insects
Badisco, L., Van Wielendaele, P., & Vanden Broeck, J. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00202 · Cited by 173
Regulation and Function of Protein Kinases and Phosphatases
Cheng, H., Qi, R. Z., Paudel, H. K., & Zhu, H. (2011) · Enzyme Research · doi:10.4061/2011/794089 · Cited by 179
SREBP-1c and lipogenesis in the liver: an update
Ferré, P., Phan, F., & Foufelle, F. (2021) · Biochemical Journal · doi:10.1042/bcj20210071 · Cited by 183
Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A., & Ess, K. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.024 · Cited by 165
PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12
Gan, X., Wang, J., Wang, C., Sommer, E. M., Kozasa, T., Srinivasula, S. M., Alessi, D. R., Offermanns, S., Simon, M. I., & Wu, D. (2012) · Nature Cell Biology · doi:10.1038/ncb2507 · Cited by 172
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.
Lu, J., Zavorotinskaya, T., Dai, Y.-M., Niu, X.-H., Castillo, J., Sim, J., Yu, J.-J., Wang, Y., Langowski, J., Holash, J., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481457 · Cited by 168
Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity
Kaadige, M. R., Looper, R., Kamalanaadhan, S., & Ayer, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901221106 · Cited by 168
Cordycepin Inhibits Protein Synthesis and Cell Adhesion through Effects on Signal Transduction
Wong, Y. Y., Moon, A., Duffin, R., Barthet-Barateig, A., Meijer, H. A., Clemens, M. J., & de Moor, C. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071159 · Cited by 167
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
Andersen, J. N., Sathyanarayanan, S., Bacco, A. D., Chi, A., Zhang, T., Chen, A. H., Dolinski, B. M., Kraus, M., Roberts, B. S., Arthur, W. T., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001065 · Cited by 164
Targeting cancer by binding iron: Dissecting cellular signaling pathways
Lui, G. Y. L., Kovačević, Ž., Richardson, V., Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2015) · Oncotarget · doi:10.18632/oncotarget.4349 · Cited by 165
The PI 3 K / A kt/m TOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies
Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 159
Translational Control during Endoplasmic Reticulum Stress beyond Phosphorylation of the Translation Initiation Factor eIF2α
Guan, B., Krokowski, D., Majumder, M., Schmotzer, C. L., Kimball, S. R., Merrick, W. C., Koromilas, A. E., & Hatzoglou, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.543215 · Cited by 161
SMN regulates axonal local translation via miR-183/mTOR pathway
Kye, M. J., Niederst, E. D., Wertz, M. H., Gonçalves, I. D. C. G., Akten, B., Dover, K. Z., Peters, M., Rießland, M., Neveu, P. A., Wirth, B., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu350 · Cited by 166
mTORC1 pathway in DNA damage response
Ma, Y., Vassetzky, Y. S., & Dokudovskaya, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.06.011 · Cited by 157
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
Ching, C. B., & Hansel, D. E. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.133 · Cited by 155
Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis
Lam, K., Zheng, X., Forestieri, R., Balgi, A. D., Nodwell, M., Vollett, S., Anderson, H. J., Andersen, R. J., Av‐Gay, Y., & Roberge, M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002691 · Cited by 153
mTOR function and therapeutic targeting in breast cancer.
Hare, S. H., & Harvey, A. (2017) · PubMed Central · Cited by 150
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
Amin, D. N., Campbell, M. R., & Moasser, M. M. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.08.007 · Cited by 143
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
Madhunapantula, S. V., & Robertson, G. P. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00585.x · Cited by 148
A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation
Pezze, P. D., Sonntag, A., Thien, A., Prentzell, M. T., Gödel, M., Fischer, S., Neumann‐Haefelin, E., Huber, T. B., Baumeister, R., Shanley, D. P., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002469 · Cited by 148
Salmonella Typhimurium disrupts Sirt1/AMPK checkpoint control of mTOR to impair autophagy
Ganesan, R., Hos, N. J., Gutiérrez, S., Fischer, J., Stepek, J. M., Daglidu, E., Krönke, M., & Robinson, N. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006227 · Cited by 143
From Molecules to Management: Mechanisms and Consequences of Locust Phase Polyphenism
Cullen, D. A., Cease, A., Latchininsky, A. V., Ayali, A., Berry, K., Buhl, C., Keyser, R. D., Foquet, B., Hadrich, J. C., Matheson, T., et al. (2017) · Advances in insect physiology · doi:10.1016/bs.aiip.2017.06.002 · Cited by 147
Proton-Assisted Amino Acid Transporter PAT1 Complexes with Rag GTPases and Activates TORC1 on Late Endosomal and Lysosomal Membranes
Ogmundsdottir, M. H., Heublein, S., Kazi, S., Reynolds, B., Visvalingam, S. M., Shaw, M. K., & Goberdhan, D. C. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036616 · Cited by 149
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription
Sheng, Z., Ma, L., Sun, J. E., Zhu, L. J., & Green, M. R. (2011) · Blood · doi:10.1182/blood-2010-12-322537 · Cited by 139
Toward rapamycin analog (rapalog)-based precision cancer therapy
Meng, L.-H., & Zheng, X. F. S. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.68 · Cited by 125
Autophagy and Tumorigenesis
Roy, S., & Debnath, J. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0213-0 · Cited by 146
Quercetin nanoparticles induced autophagy and apoptosis through AKT/ERK/Caspase-3 signaling pathway in human neuroglioma cells: In vitro and in vivo
Lou, M., Zhang, L., Ji, P., Feng, F., Liu, J.-H., Chen, Y., Li, B.-F., & Wang, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.055 · Cited by 138
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.033 · Cited by 135
Targeting the RAS oncogene
Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 140
Spinal Phosphinositide 3-Kinase–Akt–Mammalian Target of Rapamycin Signaling Cascades in Inflammation-Induced Hyperalgesia
Xu, Q., Fitzsimmons, B., Steinauer, J., Neill, A. O., Newton, A. C., Hua, X., & Yaksh, T. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2139-10.2011 · Cited by 145
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
Ghobrial, I. M., Gertz, M. A., LaPlant, B. R., Camoriano, J. K., Hayman, S. R., Lacy, M. Q., Chuma, S., Harris, B. N., Leduc, R., Rourke, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0994 · Cited by 135
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy
Huang, H., Kang, R., Wang, J., Luo, G. G., Yang, W. Z., & Zhao, Z. (2012) · Autophagy · doi:10.4161/auto.22791 · Cited by 133
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Cappellini, A., Ognibene, A., & McCubrey, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.04.005 · Cited by 134
Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease
Ma, T., & Klann, E. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07506.x · Cited by 140
Altered Skeletal Muscle Lipase Expression and Activity Contribute to Insulin Resistance in Humans
Badin, P.-M., Louche, K., Mairal, A., Liebisch, G., Schmitz, G., Rustan, A. C., Smith, S. R., Langin, D., & Moro, C. (2011) · Diabetes · doi:10.2337/db10-1364 · Cited by 132
“This suggests that ATGL may activate potential regulators of Ser473 Akt, such as mTORC2, by yet unknown mechanisms (37).”
Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway
Cuyàs, E., Corominas-Faja, B., Joven, J., & Menéndez, J. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0888-2_7 · Cited by 128
mTOR Complex-2 Activates ENaC by Phosphorylating SGK1
Lu, M., Wang, J., Jones, K. T., Ives, H. E., Feldman, M. E., Yao, L., Shokat, K. M., Ashrafi, K., & Pearce, D. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009111168 · Cited by 122
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
Farahani, M., Niknam, Z., Amirabad, L. M., Dashatan, N. A., Koushki, M., Nemati, M., Pouya, F. D., Rezaei–Tavirani, M., Rasmi, Y., & Tayebi, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112420 · Cited by 126
FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade
Kuchay, S., Duan, S., Schenkein, E., Peschiaroli, A., Saraf, A., Florens, L. A., Washburn, M. P., & Pagano, M. (2013) · Nature Cell Biology · doi:10.1038/ncb2731 · Cited by 125

Authors: Huang, J., & Manning, B. D.
Affiliations: Harvard University (US)
Corresponding author: Manning, Brendan D.
ORCID: Huang, Jingxiang
Manning, Brendan D.
Venue: Biochemical Society Transactions
Publisher: Portland Press Ltd.
Published: 2009-01-20
Volume: 37
Issue: 1
Pages: 217-222
ISSN: 0300-5127 (ISSN-L)
1470-8752
DOI: 10.1042/bst0370217
PMC: PMC2778026
OpenAlex: W2065322400
Cited by: 724
References: 35
Citations by year: 2026: 17 · 2025: 18 · 2024: 21 · 2023: 22 · 2022: 31 · 2021: 31 · 2020: 37 · 2019: 40 · 2018: 49 · 2017: 40 · 2016: 38 · 2015: 53 · 2014: 60 · 2013: 51 · 2012: 67
FWCI: 5.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Biochemical Society Transactions (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA122617, P01CA120964)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: Akt, TSC1/TSC2 complex, tuberous sclerosis complex, mTORC1, mTORC2, PI3K signaling, Rheb, Akt phosphorylation, negative feedback regulation, growth factor signaling, tumor growth
MeSH terms: Tuberous Sclerosis Complex 2 Protein, Animals, Humans, Protein Kinases, Transcription Factors, Phosphatidylinositol 3-Kinases, Feedback, Physiological, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A complex interplay between Akt, TSC2 and the two mTOR complexes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks